Long-Term Sequelae in Patients Treated for Recurrent CNS Relapses of Pediatric B-Cell Acute Lymphoblastic Leukemia: 20-Year Follow-Up, Neurological Consequences, and Survivorship Burden—A Case Report and Literature Review
Open Access
- 17 September 2026
- journal article
- case report
- Published by MDPI AG in Pediatric Reports
- Vol. 18 (5) , 121
Abstract
Central nervous system (CNS) relapse remains a major cause of treatment failure in pediatric acute lymphoblastic leukemia (ALL). Repeated isolated CNS relapse is particularly rare and associated with poor prognosis, while optimal therapeutic strategies remain insufficiently defined. Intensified CNS-directed therapy may improve disease control but is also associated with substantial long-term neurotoxicity and survivorship burden. We present the case of a boy with favorable-risk B-cell ALL who developed two isolated CNS relapses despite a good initial response to frontline therapy and absence of classical CNS relapse risk factors. The second relapse was associated with extensive meningeal involvement and optic nerve infiltration. The patient underwent intensive multimodal CNS-directed therapy, including repeated intrathecal chemotherapy, liposomal cytarabine administered according to the IntReALL 2010 protocol, cranial irradiation, and allogeneic hematopoietic stem cell transplantation (alloHSCT) from a matched sibling donor. Durable long-term remission was achieved despite the extremely unfavorable prognosis that is associated with a second isolated CNS relapse. A twenty-year follow-up extending into early adulthood revealed substantial late complications, including epilepsy, transient ischemic attack, optic nerve injury, endocrinopathies, obesity, secondary thyroid malignancy, neurocognitive difficulties, and depression requiring long-term psychiatric and psychological support. The present case illustrates the complex balance between effective CNS disease control and cumulative treatment-related neurotoxicity in pediatric ALL survivors. It also highlights the cumulative CNS injury and long-term survivorship burden that is associated with repeated CNS relapse and multimodal CNS-directed therapy.Keywords
All Related Versions
Funding Information
- Mundipharma Polska Sp. z o.o.,
This publication has 33 references indexed in Scilit:
- Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor StudyThe Lancet Oncology, 2025
- Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patientsCancer Chemotherapy and Pharmacology, 2024
- Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemiaThe Lancet Haematology, 2021
- Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent dataCancer and Metastasis Reviews, 2020
- Flow cytometric detection of liposomal cytarabine in cerebrospinal fluid of patients treated with intrathecal chemotherapyCytometry Part B: Clinical Cytometry, 2012
- Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantationAnnals of Hematology, 2008
- Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemiaAnnals of Hematology, 2008
- Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous SystemTransplantation and Cellular Therapy, 2008
- Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant ResearchLeukemia, 2007
- High incidence of secondary brain tumours after radiotherapy and antimetabolitesThe Lancet, 1999